Long-term Effect of the β2-Receptor Agonist Procaterol on Daily Life Performance and Exercise Capacity in Patients with Stable Chronic Obstructive Pulmonary Disease

Shioya, Takanobu; Satake, Masahiro; Sato, Kazuhiro; Sano, Masaaki; Sugawara, Keiyu; Takahashi, Hitomi; Honma, Mitsunobu

doi:10.1055/s-0031-1296462

Cited by 7 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oga et al58 observed statistically significant (but not MCID) improvements in both the 6MWD (6 m increase, P < 0.05) and CWR cycle ergometry (34 s increased endurance, P < 0.001) compared with placebo, following a single dose of 400 μg oxitropium. However, in the study by Shioya et al,50 6MWD in patients receiving 600 μg oxitropium was not shown to differ significantly from baseline after 12, 24 or 52 weeks of treatment. A total of six oxitropium studies60–65 were included in the review of Liesker et al,11 and in five of these studies60,62–65 a statistically significant improvement in exercise performance was observed, though these did not achieve a definite MCID.…”

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 80%

“…Shioya et al50 demonstrated clinically significant improvements in walking distance using the 6MWD (42 m, P < 0.05) together with significant improvements in dysnpea and FEV 1 . In the study by Sukisaki and colleagues,51 statistically significant improvements in the incremental SWT (37 m, P < 0.001) were reported, despite no significant improvements in FEV 1 , though this distance is below the MCID.…”

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 97%

“…More recently, two studies50,51 have evaluated the impact of procaterol on exercise performance. Shioya et al50 demonstrated clinically significant improvements in walking distance using the 6MWD (42 m, P < 0.05) together with significant improvements in dysnpea and FEV 1 .…”

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 99%

“…7,12,46,50,52–58 In general, they are recommended for the management of mild COPD and as required in symptomatic patients 10,59. Prior to the availability of the once-daily anticholinergic, tiotropium, short-acting anticholinergics had been used for chronic treatment across all severities of the disease.…”

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 99%

“…Two studies examining the effect of oxitropium on exercise performance have been published since 1999 50,58. Oga et al58 observed statistically significant (but not MCID) improvements in both the 6MWD (6 m increase, P < 0.05) and CWR cycle ergometry (34 s increased endurance, P < 0.001) compared with placebo, following a single dose of 400 μg oxitropium.…”

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 99%

See 4 more Smart Citations

Impact of bronchodilator therapy on exercise tolerance in COPD

Aguilaniu¹

2010

COPD

View full text Add to dashboard Cite

Exercise tolerance is an important parameter in patients with COPD and a primary goal of treatment is to reduce dyspnea to facilitate physical activities and improve health-related quality of life. This review examines the link between expiratory flow limitation and dyspnea to explain the rationale for the use of bronchodilators and review the characteristics of different types of exercise tests, with specific focus on which tests are likely to show a response to bronchodilators. An earlier literature search of studies published up to 1999 assessed the effects of bronchodilatort therapy on dypsnea and exercise tolerance among patients with COPD. This current review examines the clinical evidence published since 1999. Thirty-one randomized studies of exercise tolerance associated with short- and long-acting β2-agonists and anticholinergics were identified. Evidence for the efficacy of bronchodilators in enhancing exercise capacity is often contradictory and possibly depends on the exercise test and study methodology. However, further studies should confirm the benefit of long-acting bronchodilators in improving spontaneous everyday physical activities.

show abstract

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 80%

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 97%

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 99%

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 99%

Section: Short-acting Bronchodilators (Table 1)mentioning

confidence: 99%

See 3 more Smart Citations

Impact of bronchodilator therapy on exercise tolerance in COPD

Aguilaniu¹

2010

COPD

View full text Add to dashboard Cite

show abstract

Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators

Kitaguchi

Komatsu

Hanaoka

et al. 2013

Respiratory Medicine

View full text Add to dashboard Cite

The purpose of this study was to clarify the additive efficacy of short-acting β(2)-agonists (SABA) or muscarinic antagonists (SAMA) on dynamic hyperinflation and exercise tolerance in patients with chronic obstructive pulmonary disease (COPD) who had been treated with long-acting bronchodilators. Thirty-two patients with stable COPD who had been treated with long-acting bronchodilators, including long-acting muscarinic antagonists (LAMA), were examined by pulmonary function tests, dynamic hyperinflation evaluated by the method of step-wise metronome-paced incremental hyperventilation, and the incremental shuttle walking test before and after inhalation of SABA or SAMA. The additive efficacy of the two drugs was analyzed. Inhalation of SABA and SAMA improved airflow limitation and dynamic hyperinflation in stable COPD patients who had been treated with LAMA. Inhalation of SABA decreased respiratory resistance and the difference in respiratory resistance at 5 Hz and 20 Hz. On the whole, the additive efficacy of SABA on airflow limitation and dynamic hyperinflation was superior to that of SAMA. Furthermore, inhalation of SABA resulted in relief of breathlessness during exercise and significant improvement in exercise capacity. Inhalation of SABA resulted in significant improvement in exercise tolerance, which may have been due to improvement in dynamic hyperinflation. Single use of SABA before exercise, in addition to regular treatment with LAMA, may therefore be useful in stable COPD patients.

show abstract

Inhibitory effect of procaterol on exercise dynamic lung hyperinflation during the 6-min walk test in stable patients with chronic obstructive pulmonary disease

Satake

Takahashi

Sugawara

et al. 2011

Arzneimittelforschung

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to evaluate the inhibitory effect of procaterol (procaterol hydrochloride, CAS 62929-91-3) on exercise dynamic lung hyperinflation during the 6-min walk test (6MWT) in stable chronic obstructive disease (COPD) patients. Fourteen patients with stable COPD who were referred to our clinic between July 2008 and October 2009 were evaluated in this study. After the inhalation of procaterol, values for the lung function test, including vital capacity, inspiratory capacity, forced vital capacity, and FEV1/FEV1pred showed a significant improvement. Compared to the baseline assessment, the 6-min walk distance increased by a mean of 20.5 m when measured after inhalation of procaterol (512.4 +/- 90.7 m vs. 532.9 +/- 79.8 m, p < 0.05). During the 6MWT, inspiratory capacity decreased significantly with time. The inspiratory capacity after inhalation of procaterol was improved significantly compared with placebo. The Borg scale increased significantly during the 6MWT and was attenuated after inhaling procaterol hydrochloride, though the difference between the two groups was not statistically significant. In the present study, there was a significant attenuation in exercise dynamic lung hyperinflation, suggesting the important role of the beta2-receptor agonist procaterol in the treatment of COPD. It is therefore likely that most patients with COPD may derive considerable benefit from bronchodilator therapy with procaterol.

show abstract

Long-term Effect of the β2-Receptor Agonist Procaterol on Daily Life Performance and Exercise Capacity in Patients with Stable Chronic Obstructive Pulmonary Disease

Cited by 7 publications

References 13 publications

Impact of bronchodilator therapy on exercise tolerance in COPD

Impact of bronchodilator therapy on exercise tolerance in COPD

Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators

Inhibitory effect of procaterol on exercise dynamic lung hyperinflation during the 6-min walk test in stable patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About